Search

everythinglearnresearchcommunity

for

Search:↓

IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.

A man was diagnosed with a rare form of lupus after showing unique skin symptoms that responded well to treatment.

Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Mycophenolate mofetil was effective for most patients in treating scarring hair loss, but some had side effects.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Sintilimab treatment caused hair loss but led to complete tumor remission.

BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.

Ustekinumab might work for severe psoriasis, but more research is needed to be sure.

Correct diagnosis is crucial for treating overlapping conditions like NMOSD and SLE effectively.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

A patient experienced severe hair loss after getting an mRNA COVID-19 vaccine.

Some medications can improve skin conditions, while lifestyle factors like smoking and drinking may worsen them; treatments like monoclonal antibodies and imiquimod cream show promise for certain skin diseases.

IL-17C is important in inflammatory skin diseases and could be a target for treatment.

Biological therapy boosts the immune system to effectively fight melanoma.

An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.

Patients with severe alopecia areata have higher levels of MIF, which decrease after successful treatment.

A man with rare skin changes on his fingers was diagnosed with multiple myeloma-linked amyloidosis.

New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

Immunosuppressive therapy helps manage autoimmune diseases but carries risks like infection and potential for malignancy.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Systemic corticosteroids may effectively treat follicular mucinosis.

Bortezomib chemotherapy can cause temporary skin rashes.

Methotrexate effectively controls eye inflammation in Japanese patients with non-infectious uveitis but requires careful monitoring for side effects.

Dupilumab for skin problems might reactivate hair loss in some patients.

Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.